Study Treatment and Procedures
toxicity, fractures, bone loss, hypercalcemia
BONE LOSS, HYPERCALCEMIA
Patients were enrolled sequentially into cohorts, and treatments were administered in 28-day cycles. At least 15 patients were planned for enrollment and 20 patients were enrolled in the phase Ib study. In all cohorts, 200 mg of encorafenib was administered orally once daily and cetuximab was administered intravenously once weekly starting with 400 mg/mPatients who developed hypercalcemia (any grade) were treated with bisphosphonates per institutional standards. Due to emerging bone toxicity, patients were monitored by DEXA scan at screening, cycle 3 day 1, every 16 weeks, and as clinically indicated (following protocol amendment); patients who demonstrated bone loss either discontinued WNT974 treatment (in the case of bone fractures or new DEXA 